Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/21/23
End: 03/13/25
Due: 03/13/26
Phase: N/A
Priority: Normal
Start: 01/31/25
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 03/20/25
End: 09/30/27
Due: 09/30/28
Phase: N/A
Priority: Normal
Start: 09/26/23
End: 03/31/31
Due: 03/31/32
Phase: N/A
Priority: Normal
Start: 07/27/22
End: 11/17/23
Due: 11/17/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of STAR-0215 in Participants With Hereditary Angioedema | NCT05695248 | Astria Therapeutics, Inc. | user2@example.com | None | 2023-02-21 | 2025-03-13 | 2026-03-13 | - | - | 2025-07-14 |
| A Study of STAR-0310 in Healthy Adult Participants | NCT06782477 | Astria Therapeutics, Inc. | user2@example.com | None | 2025-01-31 | 2026-01-31 | 2027-01-31 | - | - | 2025-07-14 |
| A Study of Navenibart in Participants With Hereditary Angioedema | NCT06842823 | Astria Therapeutics, Inc. | user2@example.com | None | 2025-03-20 | 2027-09-30 | 2028-09-30 | - | - | 2025-07-14 |
| A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema | NCT06007677 | Astria Therapeutics, Inc. | user2@example.com | None | 2023-09-26 | 2031-03-31 | 2032-03-31 | - | - | 2025-07-14 |
| A Study of STAR-0215 in Healthy Adult Participants | NCT05477160 | Astria Therapeutics, Inc. | user2@example.com | None | 2022-07-27 | 2023-11-17 | 2024-11-17 | - | - | 2025-07-14 |